A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Hyperbilirubinemia, Neonatal

In brief

It is a normal process in the human body for red blood cells to die, which makes bilirubin. Bilirubin is cleared away through the liver. Some babies are born with livers that don't work well enough yet, or their red blood cells are dying too fast, so the baby looks yellow (jaundice). This means there is too much bilirubin in the body. It can be dangerous if a baby's bilirubin gets too high. Phototherapy is what they call the lights they shine on newborn babies to help the liver get rid of bilirubin. This study tests an experimental drug to see if it can reduce how much bilirubin is being made in the first place.

Key facts

Study ID
NCT00850993
Run by
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
People needed
58
Starts
2008-08-01
Expected to finish
2012-05-01
Last updated by the study team
2019-10-30

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.